With increasing complexity of novel biopharmaceuticals comes new challenges in developing stable cell lines to produce these treatments. Strategies to gain more information on critical post translational modifications in early development can significantly accelerate drug development timelines.

  • How to utilize icIEF-UV/MS to identify sequence variants
  • How this information can be used to create a mitigation strategy
  • What more information in less time means to groups throughout process development

Presented by

Kristen Nields PhD

Principal Scientist

J&J Innovative Medicines